RSS Feeds
Rhabdomyolysis with Cardiac Involvement and Acute Renal Failure in a Patient Taking Rosuvastatin and Fenofibrate
- James H.E. Ireland, MD;
- Christoph H. Eggert, MD;
- Christopher J. Arendt, PharmD; and
- Amy W. Williams, MD
- From Mayo Clinic College of Medicine, Rochester, MN 55905.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, have revolutionized therapy for hypercholesterolemia. Although uncommon, statin-induced myopathy is a well-described side effect (1). A new statin, rosuvastatin, has been particularly scrutinized because rhabdomyolysis and renal failure occurred …
